Ameriprise Financial Inc. increased its stake in Shire PLC (NASDAQ:SHPG) by 86.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,275 shares of the biopharmaceutical company’s stock after buying an additional 26,938 shares during the period. Ameriprise Financial Inc.’s holdings in Shire PLC were worth $10,724,000 as of its most recent filing with the SEC.
Several other large investors also recently modified their holdings of the company. FTB Advisors Inc. raised its stake in shares of Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 18 shares during the last quarter. Duncker Streett & Co. Inc. bought a new stake in shares of Shire PLC during the second quarter valued at approximately $111,000. Quadrant Capital Group LLC raised its stake in shares of Shire PLC by 157.6% in the second quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 372 shares during the last quarter. Ropes Wealth Advisors LLC bought a new stake in shares of Shire PLC during the second quarter valued at approximately $114,000. Finally, West Oak Capital LLC bought a new stake in shares of Shire PLC during the second quarter valued at approximately $126,000. Institutional investors own 24.26% of the company’s stock.
Shire PLC (NASDAQ:SHPG) traded down 0.155% during trading on Friday, reaching $194.519. The company’s stock had a trading volume of 1,019,754 shares. The firm has a market capitalization of $57.94 billion, a price-to-earnings ratio of 40.424 and a beta of 1.11. Shire PLC has a 52-week low of $147.60 and a 52-week high of $231.32. The stock’s 50-day moving average is $196.28 and its 200 day moving average is $185.51.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.03 by $0.35. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The business had revenue of $2.43 million for the quarter, compared to the consensus estimate of $2.28 billion. During the same period last year, the business earned $2.63 EPS. The firm’s revenue was up 55.9% compared to the same quarter last year. On average, analysts predict that Shire PLC will post $12.92 EPS for the current fiscal year.
The business also recently disclosed a dividend, which will be paid on Friday, October 7th. Investors of record on Friday, September 9th will be paid a $0.139 dividend. The ex-dividend date is Wednesday, September 7th. Shire PLC’s payout ratio is 15.63%.
Several brokerages have commented on SHPG. Morgan Stanley restated an “overweight” rating on shares of Shire PLC in a research report on Friday, June 3rd. Piper Jaffray Cos. reiterated a “neutral” rating and issued a $174.00 price objective on shares of Shire PLC in a research report on Friday, July 15th. Citigroup Inc. reiterated a “buy” rating on shares of Shire PLC in a research report on Wednesday, August 3rd. Jefferies Group boosted their price objective on shares of Shire PLC from $223.00 to $262.00 and gave the stock a “buy” rating in a research report on Friday, June 3rd. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of Shire PLC in a research report on Wednesday, June 15th. Five research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $230.67.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.